AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 31 min read$GEHC

GE HealthCare (NASDAQ: GEHC) exec gives up 856 shares for taxes

GE HealthCare (GEHC) disclosed that CEO Philip Rackliffe had 856 shares withheld for tax obligations related to vested restricted stock units. The shares were withheld at $71.23 per share on September 1, 2026, and were not open-market sales. Rackliffe holds 42,331 shares post-transaction.

Original reporting
stocktitan.net
Published Sep 3, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 12:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$GEHC
Neutral
high confidence
Mentioned
$GEHC
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$GEHCNeutralLow
01

Why it matters

The filing provides transparency but adds no new material information for investors.

02

Market read

Minor insider filing with negligible trading relevance.

03

What to watch

Potential future dilution if additional RSUs vest, but not immediate.

Relevance 4/10Novelty 3/10Timing: Sep 1 2026 filing

Background

Form 4 disclosures are required for insider transactions; tax withholdings are routine when RSUs vest.

Company-level read

Ticker impact

$GEHCNeutralHigh confidence
Context

CEO Philip Rackliffe reported withholding of 856 shares to cover tax on RSU vesting on Sep 1 2026.

Expected impact

No material impact expected.

Evidence & confidence

The transaction is a tax withholding, not a market sale, and the total value (~$61k) is negligible for a large cap.

Market effects

Sector

None; isolated insider filing.

Regional

None; US market only.

Global

None

Counterpoint

What could challenge this read

Even small insider withholdings can signal confidence; however, the lack of a sale suggests no negative sentiment.

Key entities

  • Executive
    Philip Rackliffe

    CEO of the AIS segment at GE HealthCare

  • Company
    GE HealthCare Technologies Inc.

    Provider of medical imaging and diagnostics equipment

Read at source← All news

Related articles

SEP 17
$GEHCMedAI 8/10

GE HealthCare stock maintained at Buy by BTIG on imaging tech

BTIG maintained a Buy rating and $79 price target for GE HealthCare (GEHC) after positive feedback on its new photon-counting CT system. GEHC stock is down 22% YTD but is considered undervalued. The company reported Q2 revenue of $5.295B, beating estimates, and raised its price target to $85. GEHC's backlog reached $23.9B, indicating strong demand.

investing.com2 min
SEP 17
$GEHCMedAI 8/10

GE HealthCare (GEHC) Reportedly Eyes $1B Sofie Deal. What Would Ownership Add?

GE HealthCare (GEHC) is reportedly in talks to acquire Sofie Biosciences for $1B. Sofie holds U.S. rights to F-18 FAPI-74, a radiotracer for PET scans. GEHC already licensed global rights to Gallium-68 FAPI-46 and non-U.S. rights to F-18 FAPI-74. Sofie operates seven radiopharmacies producing F-18 FAPI-74. The deal's value depends on additional rights, manufacturing earnings, and operational benefits.

insidermonkey.com3 min
SEP 14
$GEHCHighAI 9/10

GE HealthCare Reportedly In Talks To Buy Sofie Biosciences For About $1 Billion

GE HealthCare is reportedly in advanced talks to acquire Sofie Biosciences for around $1 billion, according to the Financial Times. Sofie specializes in radiopharmaceuticals for PET imaging, which could expand GE HealthCare's diagnostics portfolio and create recurring revenue streams. The deal would mark GE HealthCare's second major acquisition since its 2023 separation from General Electric.

pulse2.com3 min
SEP 14
$GEHCHighAI 9/10

GE HealthCare Technologies in talks to buy Sofie Biosciences

GE HealthCare Technologies is in talks to acquire Sofie Biosciences for approximately $1 billion, according to the Financial Times. The deal, which could be announced next week, would be GE HealthCare's second major acquisition since its split from General Electric in 2024. Sofie specializes in radioactive chemicals used in cancer scans, and the acquisition would strengthen GE HealthCare's pharmaceutical diagnostics division.

medicalbuyer.co.in2 min